Recursion vs Xaira Therapeutics (2026)
The established platform against the best funded newcomer in the field. Recursion generates its own biology at industrial scale, feeding machine learning on cellular imaging and multiomic data, with disclosed partnership economics as a listed company and a pipeline that has been narrowed and reported on publicly. Xaira launched in 2024 with the largest initial funding commitment in its lead investor's history and scientific provenance drawn from the groups that produced foundational computational protein design work, and it has published essentially nothing about its platform, its access model or any development candidate. That is a reasonable position for a company this young and it is not evidence. The distinction worth holding is that provenance is public and the platform is not, and a partner should not accept one as a substitute for the other.
- The data flywheel is the asset, with high throughput cellular experimentation feeding machine learning on imaging and multiomic data at industrial scale.
- Partnership economics are disclosed as a listed registrant, so the market's valuation of the platform is visible rather than described.
- Oversight is empirical by construction, with model hypotheses tested in the wet laboratory before they advance.
- The capital commitment is the largest initial funding position in its investor's history, which buys years of runway to build a platform without partnership pressure.
- The scientific provenance is genuinely exceptional, drawn from the groups that produced foundational work in computational protein design.
- For a partner betting on a decade rather than a quarter, an unencumbered platform build has advantages a public company under quarterly scrutiny does not.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Recursion and Xaira Therapeutics are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Recursion | Xaira Therapeutics |
|---|---|---|
| Primary category | Drug Discovery AI | Drug Discovery AI |
| Founded | Not recorded | 2023 |
| Headquarters | Salt Lake City, UT | South San Francisco, CA |
| Website | recursion.com | xaira.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Recursion its top capability grade on AI Centrality and Commercial Transparency. Set against Xaira Therapeutics, Recursion grades higher on several axes, including Autonomy and Oversight Model, Model and Technology Transparency and Model Supply Chain Disclosure. Its thinnest published disclosure sits on AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards Xaira Therapeutics its top capability grade on AI Centrality. Set against Recursion, Xaira Therapeutics grades higher on HIPAA and BAA Posture and AI Liability and Recourse. Its thinnest published disclosure sits on Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Recursion or Xaira Therapeutics?
On the axes where the AI Health Index separates them, Recursion grades higher on several axes, including Autonomy and Oversight Model, Model and Technology Transparency and Model Supply Chain Disclosure, and Xaira Therapeutics grades higher on HIPAA and BAA Posture and AI Liability and Recourse. Recursion leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Recursion and Xaira Therapeutics differ most?
The widest separation the AI Health Index records between Recursion and Xaira Therapeutics is on Model Supply Chain Disclosure, where Recursion grades B and Xaira Therapeutics grades D. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do Recursion and Xaira Therapeutics grade the same?
The AI Health Index grades Recursion and Xaira Therapeutics the same on several axes, including AI Centrality, AI Safety and PHI Stewardship and AI Governance and Bias Disclosure. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have Recursion and Xaira Therapeutics not disclosed?
At the last review, at least one of Recursion and Xaira Therapeutics published thin or absent detail on Model Supply Chain Disclosure and AI Liability and Recourse. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Drug Discovery AI page.
The asymmetry here is stage rather than quality and the page should not pretend otherwise: one company has partnerships, disclosed economics and a pipeline history including a narrowed programme list, while the other launched publicly in 2024 with essentially no clinical or platform evidence yet, no disclosed access model and no development candidate. Xaira's provenance is public and its platform is not, and a buyer should be careful not to substitute one for the other. Neither publishes cohort or data provenance detail, and neither holds a located security attestation.